Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

You know Hims, right? It's the next-gen telehealth startup famous for taking the eye contact out of erectile dysfunction treatment. Of course, bedroom pills aren't all Hims peddles. The Uberized ...

Jefferies analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $25 from $21 and keeps a Hold rating on the shares. A ...

Hims & Hers’s addition of obesity drug Zepbound won’t do much to bolster its weight-loss business, analysts say.

While there's still plenty of work to be done, Hims is one of many such companies that's helping to expand healthcare options, by opening the conversation around men's health, in particular.

Shares of Hims & Hers Health (NYSE: HIMS) surged on Tuesday, closing the session up 5.25% after having been up by as much as 14% earlier. That jump came as the S&P 500 and Nasdaq Composite showed ...